Literature DB >> 1657353

Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.

T Takayama1, M Makuuchi, T Sekine, S Terui, H Shiraiwa, T Kosuge, S Yamazaki, H Hasegawa, K Suzuki, M Yamagata.   

Abstract

Indium-111-labeled tumor-infiltrating lymphocytes (111In-TIL) were transferred as an intrahepatic arterial bolus to determine their in vivo distribution in patients with hepatic malignancies. In the in vitro culture system, TIL were expanded upon simultaneous stimulation by recombinant interleukin-2 (rIL-2) and immobilized anti-CD3 monoclonal antibody. This double activation led not only to a larger cell yield, but also to a significantly more dominant subpopulation with CD4+ phenotype than occurred with activation by rIL-2 alone. Accumulations of 111In-TIL in the liver were identified by scintigraphy in all of three patients, corresponding to the tumor localization by computed tomography. Such accumulation had persisted for at least 48 hours after infusion. After intraarterial chemoimmunotherapy that included TIL, two of three patients achieved a partial therapeutic response. The authors conclude that their method of culture and transfer can facilitate the accumulation of TIL at tumor sites, which may augment the antitumor effects of adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657353     DOI: 10.1002/1097-0142(19911201)68:11<2391::aid-cncr2820681110>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

2.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

Authors:  Steven C Katz; Rachel A Burga; Elise McCormack; Li Juan Wang; Wesley Mooring; Gary R Point; Pranay D Khare; Mitchell Thorn; Qiangzhong Ma; Brian F Stainken; Earle O Assanah; Robin Davies; N Joseph Espat; Richard P Junghans
Journal:  Clin Cancer Res       Date:  2015-04-07       Impact factor: 12.531

3.  Safety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT.

Authors:  Johan Lundberg; Emma Jussing; Zhenjiang Liu; Qingda Meng; Martin Rao; Erik Samén; Rikard Grankvist; Peter Damberg; Ernest Dodoo; Markus Maeurer; Staffan Holmin
Journal:  Cell Transplant       Date:  2016-10-07       Impact factor: 4.064

Review 4.  Untangling the Knots of Regulatory T Cell Therapy in Solid Organ Transplantation.

Authors:  Gabriel Orozco; Meera Gupta; Roberto Gedaly; Francesc Marti
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 5.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 6.  Immunotherapy for liver tumors: present status and future prospects.

Authors:  Pablo Matar; Laura Alaniz; Viviana Rozados; Jorge B Aquino; Mariana Malvicini; Catalina Atorrasagasti; Manuel Gidekel; Marcelo Silva; O Graciela Scharovsky; Guillermo Mazzolini
Journal:  J Biomed Sci       Date:  2009-03-06       Impact factor: 8.410

7.  Membrane-associated lymphotoxin expression and functional analysis of lymphokine-activated killer cells derived from tumor-infiltrating lymphocytes.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Hitsumoto; N Takeuchi; S Kimura
Journal:  Jpn J Cancer Res       Date:  1993-11

8.  Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.

Authors:  Liu Zhenjiang; Martin Rao; Xiaohua Luo; Elisabeth Sandberg; Jiri Bartek; Esther Schoutrop; Anna von Landenberg; Qingda Meng; Davide Valentini; Thomas Poiret; Georges Sinclair; Inti-Harvey Peredo; Ernest Dodoo; Markus Maeurer
Journal:  EBioMedicine       Date:  2017-08-30       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.